Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.27 0.2 (0.3%) Market Cap: 12.82 Bil Enterprise Value: 12.45 Bil PE Ratio: 40.28 PB Ratio: 2.37 GF Score: 69/100

Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 03:45PM GMT
Release Date Price: $78.36 (+3.60%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Welcome, everyone, to the Bank of America London Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And also, I have Aspen Mori from my team on the line as well.

So welcome, everyone, and we're thrilled to have for this session, BioMarin speaking. And we have with us, CEO, J.J. Bienaimé. And we also have President of Worldwide R&D, Hank Fuchs. Welcome, guys.

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Yes. Maybe just to kick things, you forgot Brian. It's Brian Mueller.

Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Sorry, Brian, I'm sorry.

Brian R. Mueller;Geoffrey Christopher Meacham
BioMarin Pharmaceutical Inc. - Executive VP & CFO;BofA Merrill Lynch,

No worries.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot